Ryan Cohlhepp, President and Chief Operating Officer of Bicara Therapeutics Inc. (NASDAQ: BCAX), executed a stock sale and an option exercise on March 16, 2026, in transactions that together reshape his immediate personal holdings in the company.
Cohlhepp sold 12,500 shares of Bicara common stock for approximately $245,713. The sales were completed at a weighted average price of $19.6571 per share, with individual trade prices spanning from $19.34 up to $19.96. The sale occurred while the company's shares were trading close to their 52-week high of $20.25, after the stock posted a 76% gain over the prior six months.
On the same calendar day, Cohlhepp also exercised options to acquire 8,000 shares of Bicara common stock at an exercise price of $3.7898 per share, for a total cost of $30,318. Following the combined transactions, Cohlhepp directly holds 200,641 shares of Bicara Therapeutics.
Separately, Bicara completed an underwritten public offering that produced roughly $172.5 million in gross proceeds. In that offering the company sold 8,581,250 shares of common stock and issued pre-funded warrants to purchase 2,200,000 shares, pricing the common stock at $16.00 per share. The offering also included an additional 1,406,250 shares sold under the underwriters' option, which was exercised in full.
Earlier communications tied to the public offering had indicated an initial expectation of raising around $150 million before underwriting discounts and commissions. The company launched the transaction with plans to grant underwriters a 30-day option to buy additional shares, a provision that could increase total proceeds if exercised.
On valuation and analyst commentary, InvestingPro analysis cited in company-related materials indicates that BCAX currently appears overvalued relative to its Fair Value estimate. The platform also provides supplementary valuation metrics and additional analytical guidance for subscribers.
In analyst coverage news, Citizens has reaffirmed a Market Outperform rating on Bicara Therapeutics and maintained a $31.00 price target. Citizens indicated its valuation stems from a discounted earnings-per-share and revenue multiple framework, and noted long-term follow-up data Bicara presented at the 2026 MHNCS conference as part of its assessment.
The combination of executive share activity, option exercises, a sizable equity raise and ongoing analyst attention places Bicara in the spotlight for investors tracking insider moves and recent capital markets activity. The transactions and corporate-finance developments are documented in public filings and analyst reports referenced here.